Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

@article{Nanzigu2012PharmacokineticsOT,
  title={Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.},
  author={Sarah Nanzigu and Jan Gunnar Eriksen and Frederick E Makumbi and Shankar Lanke and Margarita Mahindi and Ronald Kiguba and Olof Beck and Qing Ma and Gene D. Morse and Lars L. Gustafsson and Paul J Waako},
  journal={HIV medicine},
  year={2012},
  volume={13 4},
  pages={193-201}
}
BACKGROUND Pharmacokinetic variability of the nonnucleoside reverse transcriptase inhibitor efavirenz has been documented, and high variation in trough concentrations or clearance has been found to be a risk for virological failure. Africans population exhibits greater variability in efavirenz concentrations than other ethnic groups, and so a better understanding of the pharmacokinetics of the drug is needed in this population. This study characterized efavirenz pharmacokinetics in HIV-infected… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Similar Papers

Loading similar papers…